60 Degrees Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SXTP research report →
Price Chart
About the company
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis.
- CEO
- Geoffrey Stuart Dow
- IPO
- 2023
- Employees
- 3
- HQ
- Washington, DC, US
Get TickerSpark's AI analysis on SXTP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $911.40K
- P/E
- -0.19
- PEG
- -0.00
- P/S
- 0.82
- P/B
- 1.15
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
- Gross Margin
- 19.42%
- Op Margin
- -774.90%
- Net Margin
- -730.23%
- ROE
- -211.59%
- ROIC
- -321.21%
Latest fiscal year · YoY change
- Revenue
- $1.01M+65.5%
- Gross Profit
- $223.78K+0.4%
- Op Income
- $-7,758,579
- Net Income
- $-7,368,325+7.3%
- EPS
- $-11.73+84.2%
- OCF Growth
- -21.3%
- FCF Growth
- -21.2%
- 52W High
- $8.62
- 52W Low
- $1.02
- 50D MA
- $1.44
- 200D MA
- $2.43
- Beta
- 2.54
- RSI (14)
- 37
- Avg Volume
- 110.08K
No earnings-call transcripts are available for SXTP yet.
- Free Float
- 96.8%
- Shares Outstanding
- 806.55K
- Float Shares
- 781.12K
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Knight Therapeutics Inc. | other | 0 |
| Jun 12, 26 | DOW GEOFFREY S | buy | 7,350 |
| May 13, 26 | Francois Eric | other | 0 |
| Dec 15, 25 | DOW GEOFFREY S | buy | 9,670 |
| Dec 11, 25 | DOW GEOFFREY S | buy | 3,613 |
| Dec 10, 25 | DOW GEOFFREY S | buy | 9,350 |
| Sep 12, 25 | DOW GEOFFREY S | other | 7,201 |
| Sep 26, 24 | Landon Kristen | other | 4,167 |
| Jan 17, 25 | Landon Kristen | other | 4,540 |
| Feb 12, 24 | Landon Kristen | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SXTP coverage
Recent articles, reports, and earnings notes.
No research on SXTP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SXTP report →60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
globenewswire.com · Aug 14
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com · Jul 30
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
globenewswire.com · Jul 29
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
globenewswire.com · Jul 8
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
globenewswire.com · Jul 1
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
globenewswire.com · Jun 11
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
globenewswire.com · May 26
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
globenewswire.com · May 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.